← All trials
NCT06942793
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2025
- Primary completion
- Oct 20, 2025
- Completion date
- Nov 15, 2025
- First posted
- Apr 24, 2025
- Last posted
- Apr 29, 2025
- Enrollment
- 396
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhaoke (Guangzhou) Pharmaceutical LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.